ISRCTN11725083已完成4 期
A phase III/IV open-label study of the immunogenicity and safety of a single dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for each of three successive years in children naïve to, or in previous receipt of the AS03B adjuvanted H1N1 (2009)
Health Protection Agency (HPA) (UK)0 个研究点目标入组 254 人开始时间: 2014年4月17日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 254
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Parent/legal guardian gives written informed consent for participation of their child in the study.
- •2. Male or female aged 4 years (+364 days) to 8 years (+364 days) on the day of consent.
- •3. Documented prior receipt of Pandemrix, or no evidence in the medical notes of never having had pandemic influenza vaccine
- •Target Gender: Male & Female; Upper Age Limit 10 years ; Lower Age Limit 5 years
排除标准
- •*Absolute exclusion criteria: The participant may not enter the study if ANY of the following apply: From Fluenz Summary of Product Characterstics (SPC):
- •1. Hypersensitivity to the active substances, to any of the excipients (e.g. gelatin; see appendix 1), to gentamicin (a possible trace residue), to eggs or to egg proteins (e.g. ovalbumin).
- •2. Children and adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids. FLUENZ is not contraindicated for use in individuals with asymptomatic HIV infection; or individuals who are receiving topical/inhaled corticosteroids or low-dose systemic corticosteroids or those receiving corticosteroids as replacement therapy, e.g. for adrenal insufficiency.
- •3. Children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wildtype influenza infection.
- •Study-specific exclusions:
- •1. Any contraindication to vaccination as specified in the ?Green Book? Immunisation against Infectious Disease, HMSO.
- •2. Known bleeding diathesis (or any condition that may be associated with a prolonged bleeding time).
- •3. Any other significant condition or circumstance which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant?s ability to participate in the study.
- •*Temporary Exclusion Criteria:
- •From the SPC:
- •1. The concurrent use of FLUENZ with antiviral agents that are active against influenza A and/or B viruses has not been evaluated. However, based upon the potential for influenza antiviral agents to reduce the effectiveness of FLUENZ, it is recommended not to administer the vaccine until 48 hours after the cessation of influenza antiviral therapy. Administration of influenza antiviral agents within two weeks of vaccination may affect the response of the vaccine. Because of this information in the SPC, should any child be given these medications the administration of LAIV would be delayed as specified.
- •Study specific:
- •1. Fever (sublingual temperature = 38°C)
- •2. Received any blood or blood products within the past 12 weeks
研究者
相似试验
进行中（未招募）
1 期
Assessing responses to annual nasal flu vaccine in children who have or have not previously been given pandemic flu vaccine.EUCTR2013-003592-35-GBPublic Health England254
进行中（未招募）
不适用
A phase 3 open-label study to evaluate the immune response and the safety of a primary series schedule that includes V419 (PR5I: hexavalent vaccine) at 2 and 6 months of age and Pediacel® (pentavalent vaccine) at 4 months of ageHealthy infants greater than or equal to 46 days and less than or equal to 74 days of age on the day of inclusionMedDRA version: 16.0Level: LLTClassification code 10054187Term: Polio immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10069543Term: Hemophilus influenzae type b immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10069593Term: Pertussis immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10054180Term: Diphtheria immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10054183Term: Tetanus immunizationSystem Organ Class: 100000004865EUCTR2012-004221-25-ESSanofi Pasteur MSD385
进行中（未招募）
1 期
Immunogenicity and safety of GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b (DTPa-IPV/Hib) conjugate vaccine.EUCTR2013-005577-43-Outside-EU/EEAGlaxoSmithKline Biologicals235
尚未招募
3 期
A Phase III Study to Evaluate the Immunogenicity and Safety of Typbar TCV Typhoid Vaccine in Adults greater than 65 Years.CTRI/2024/06/069638Bharat Biotech International Limited
已完成
3 期
A clinical study on Pentavalent vaccineCTRI/2015/06/005837Shantha Biotechnics Private Limited1,040